You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Claims for Patent: 6,685,941


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,685,941
Title:Methods of treating autoimmune disease via CTLA-4Ig
Abstract:The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
Inventor(s):Craig B. Thompson, Carl H. June
Assignee: University of Michigan System , US Department of Navy
Application Number:US08/385,194

Details for Patent 6,685,941

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company ORENCIA abatacept For Injection 125118 December 23, 2005 6,685,941 2021-02-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 July 29, 2011 6,685,941 2021-02-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 June 07, 2016 6,685,941 2021-02-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 March 30, 2017 6,685,941 2021-02-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.